Vandetanib

Chemical formula: C₂₂H₂₄BrFN₄O₂ Molecular mass: 475.354 g/mol PubChem compound: 3081361

Therapeutic indications

Vandetanib is indicated for:

Medullary thyroid cancer

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Vandetanib is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

Vandetanib is indicated in adults, children and adolescents aged 5 years and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300 mg once daily

100 or 200 mg as starting dose on the basis of BSA in mg/m² for 8 weeks, followed by a dose increase or reduction based on tolerance

Contraindications

Vandetanib is contraindicated in the following cases:

Congenital long QTc syndrome, prolonged QT interval over 480 msec, Torsades de pointes

at least one of

Congenital long QT syndrome
Prolonged QT interval
Torsades de pointes

Lactation

Medicinal products known to prolong the QTc interval and/or induce Torsades de pointes

at least one of

Drugs prolonging QT interval
Drugs inducing Torsade de Pointes
Ondansetron

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.